Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette–Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer
Crossref DOI link: https://doi.org/10.1245/s10434-016-5300-6
Published Online: 2016-07-07
Published Print: 2016-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Navai, Neema
Benedict, William F.
Zhang, Guangcheng
Abraham, Alice
Ainslie, Nancy
Shah, Jay B.
Grossman, H. Barton
Kamat, Ashish M.
Dinney, Colin P. N.
License valid from 2016-07-07